ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated
clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113,
in patients with advanced non-small cell lung cancer (NSCLC) from an
ongoing Phase 1/2 trial. The study confirms compelling clinical evidence
of the anti-tumor activity of AP26113 at multiple dose levels in
patients with anaplastic lymphoma kinase positive (ALK+) NSCLC,
including brain metastases, and initial clinical evidence of anti-tumor
activity in patients with epidermal growth factor receptor mutant
(EGFRm) NSCLC.
The study identified a recommended Phase 2 dose of 180 mg administered
orally once daily. The Phase 2 portion of the trial is now open and
enrolling patients at
See full press release Posted in: News, Guidance, Contracts, Management, Global